We acknowledge that the study of earlier and middle-stage physiological and clinical endpoints is an important feature aside from ascertaining safety, and further studies could provide a more specific evaluation of the coagulation system in COVID-19 patients treated with bradykinin inhibitors. Here, KNG1 is linked to COVID-19.